OTHER NEWS - Jan. 9, 1995

Gensia to Delay Approval Bid for Heart Drug: The San Diego-based company announced that it will delay a request for approval of a heart drug clone after it failed a test on people. Gensia Inc., whose shares last year declined 80% amid the failure of another heart drug, said it plans to delay by at least three months filing an application seeking approval of a copy of Pfizer’s Procardia XL, a once-a-day heart medicine that generated $1.2 billion of sales in 1993. Gensia’s version, whose chemical name is nifedipine, failed during a test on people to prove equivalent to the brand-name drug, the company said.